BMEZ:NYE-BlackRock Health Sciences Trust II (USD)

COMMON STOCK | |

Last Closing

USD 15.79

Change

+0.07 (+0.45)%

Market Cap

USD 1.63B

Volume

0.19M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Address: 50 Hudson Yards, New York, NY, United States, 10001

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-26 )

Largest Industry Peers for

Symbol Name Price(Change) Market Cap
TBB AT&T Inc

+0.02 (+0.08%)

USD 151.71B
PRS Prudential Financial Inc

-0.02 (-0.08%)

USD 44.13B
ALL-PB The Allstate Corporation

-0.02 (-0.08%)

USD 33.74B
SOJC Southern Co

+0.05 (+0.20%)

USD 24.81B
AIZN Assurant Inc

+0.12 (+0.53%)

USD 9.38B
RZB Reinsurance Group of America I..

+0.08 (+0.32%)

USD 8.87B
PCG-PA Pacific Gas and Electric Compa..

-0.13 (-0.52%)

USD 6.61B
PCG-PB Pacific Gas and Electric Compa..

N/A

USD 5.92B
UNMA Unum Group

-0.07 (-0.25%)

USD 5.86B
PCG-PD Pacific Gas and Electric Compa..

N/A

USD 5.42B

ETFs Containing BMEZ

YYY Amplify High Income ETF 2.97 % 0.50 %

+0.02 (+0.16%)

USD 0.52B
PCEF Invesco CEF Income Compos.. 0.00 % 0.50 %

+0.07 (+0.16%)

USD 0.81B

Market Performance

  Market Performance vs. Industry/Classification () Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 7.78% N/A N/A 48% F
Dividend Return 9.12% N/A N/A 97% N/A
Total Return 16.90% N/A N/A 69% C-
Trailing 12 Months  
Capital Gain 9.35% N/A N/A 37% F
Dividend Return 10.54% N/A N/A 94% A
Total Return 19.89% N/A N/A 48% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -6.49% N/A N/A 12% F
Dividend Return -0.21% N/A N/A 23% F
Total Return 6.27% N/A N/A 87% B+
Risk Return Profile  
Volatility (Standard Deviation) 24.29% N/A N/A 42% F
Risk Adjusted Return -0.88% N/A N/A 24% F
Market Capitalization 1.63B N/A N/A 64% D

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Positive cash flow

The company had positive total cash flow in the most recent four quarters.

What to not like:

There is nothing we particularly dislike